Search 

Swiss- Israeli based company, fuses the know how of specialists in the pahrmacology and delivery fields with the aim to bring to the market novel drugs based on cannabinoid molecules as stand alone, and synergistic combinations with proper drug delivery technologies

Cor-Act Advanced Technologies, developing a life supporting system, for patients dying from chronic heart failure). Cor-Act will shortly launch the first fully implantable, Cardiac Assist Device with no blood contact. Our solution is designed as a cost- effective technology to solve the growing gap between of patients waiting for a transplant / mechanical support and the actual expensive available therapies. The Cor-Act’s Cardiac Assist Device system incorporates a miniaturized implantable pump connected to silicone elements which are pressing the myocardium.

CytoReason is a big-data analytics company specializing in immunotherapy using its proprietary Cell-Centered Model. The proprietary machine-learning engine enhances its performance with each new dataset introduced, leveraging hundreds of published and unpublished immunotherapy datasets. Its prior knowledge allows for ever-improving accuracy, translating high-resolution measurements to specific immune-cellular interactions that extend beyond the data provided by the customer and can be translated to valuable IP. CytoReason’s technology has yielded 2 pending patents, 7 scientific collaborations and 12 peer reviewed publications

immuno-oncology

inflammatory diseases

inflammatory autoimmune 

big data

biomarker

Our technology integrates different genomic and proteomic measurements with clinical data and predicts cellular immunological pathways.

The proprietary machine-learning engine enhances its performance with each new dataset introduced, leveraging hundreds of published and unpublished immunotherapy trials. Its prior knowledge allows for ever-improving accuracy, translating high-resolution measurements to specific immune-cellular interactions. The system generates immune interaction networks that extend beyond the data provided by the customer.  

CytoReason is generating valuable IP and Know-How for biotech and pharmaceutical companies, universities and research institutions throughout their basic research, drug development, and clinical trials. 

Drooms AG is a leading European provider of secure cloud solutions. This software specialist facilitates highly secure access to confidential documents as well as the ability to safely exchange them with third parties beyond company firewalls. Confidential business processes, such as financing and licensing projects or Board Communication are handled securely, transparently and efficiently with Drooms. Headquartered in Frankfurt, Germany´s banking hub, Drooms is also expanding its global market presence and now has offices  in Munich, London, Paris, Amsterdam, Zug, Madrid, Milan and Vienna. The company is well positioned  to facilitate large-scale local and multi-jurisdictional transactions. Their professional expertise, top-tier reputation and innovative processes have laid the groundwork for a  growing reputation in this market space. Selected References include Astellas, Hormosan, HRA Pharma, Novartis, NovImmune SA and Siemens.

Gynotech is a developer of SMAT solutions for uro-gynecology conditions such as vaginal prolapse  and urinary incontinence.

Gynotech has developed the first smart, dynamic pessary that automatically adjust its size in response to the changing intr-abdominal pressures and thus provides a much better prevention of prolapse and urinary leakages.

The device is still at a development stage.

Musli Thyropeutics is a clinical stage pharmaceutical company addressing high-grade cancers. The company's patented fix-dose combination is based on recent scientific findings. Musli is targeting Glioblastoma Multiforme and Brain Metastases as-well-as Lung cancer and other aggressive high-grade cancers. Musli is preparing for Phase 2/3 clinical trials starting in 2018. Our innovative adjunct approach to current standard of care is expected to facilitate quick penetration to some of the largest markets in oncology, composing a multi-billion opportunity.

Nanosynex is saving lives from superbugs.

Our fight starts by diagnosing bacterial resistance to antibiotics in record time, using microfluidics.

Our test will help doctors determine the most appropriate antibiotic treatment for their patients and provide same-day results, which will reduce the spread of resistant bacteria and significantly lower the burden on healthcare costs.

This revolutionary scientific development is supported by a Proof of Concept from the lab of Prof. Levenberg, Dean of the Technion Biomedical Engineering Faculty.

Antimicrobial resistance 

Rapid test 

In vitro diagnostics

Microfluidics 

Technion Technology Transfer

A test to check bacterial resistance composed of disposable cards and a benchtop reader

Launched in Jan-2016, Paragate Medical is an Israeli innovative startup, aiming to revolutionize the heart failure epidemic management by introducing the first implantable medical device that actively and continuously prevents fluid overload in congestive heart failure patients. The device absorbs systemic extracellular fluid and drains it to the urinary system in a safe and controlled manner.

With its encouraging pre-clinical results and strong IP coverage, the company is currently looking to complete series A to support European based operation towards FIM trials.

Medical Device, Cardiology, Heart Failure, Minimally invasive implantable, Early Stage

Paragate's IPU is a minimally invasive, fully implantable device that continuously and actively drains excess systemic extracellular fluid, maintaining fluid overloaded heart failure patients in normal volumes and reducing the need for repeated hospitalizations for acute treatments.